Epizyme Company Profile (NASDAQ:EPZM)

About Epizyme (NASDAQ:EPZM)

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EPZM
  • CUSIP: N/A
  • Web: www.epizyme.com
Capitalization:
  • Market Cap: $1.03 billion
  • Outstanding Shares: 67,786,000
Average Prices:
  • 50 Day Moving Avg: $17.81
  • 200 Day Moving Avg: $15.45
  • 52 Week Range: $8.38 - $20.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.21
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $17.06 million
  • Price / Sales: 69.93
  • Book Value: $2.57 per share
  • Price / Book: 6.85
Profitability:
  • EBITDA: ($120,120,000.00)
  • Return on Equity: -63.10%
  • Return on Assets: -49.92%
Debt:
  • Current Ratio: 7.71%
  • Quick Ratio: 7.71%
Misc:
  • Average Volume: 603,081 shs.
  • Beta: 2.22
  • Short Ratio: 16.38
 

Frequently Asked Questions for Epizyme (NASDAQ:EPZM)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) posted its earnings results on Friday, August, 4th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.08. The company had revenue of $10 million for the quarter, compared to analysts' expectations of $3.95 million. The business's revenue was up 2027.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.49) earnings per share. View Epizyme's Earnings History.

When will Epizyme make its next earnings announcement?

Epizyme is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Epizyme.

Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?

11 equities research analysts have issued twelve-month price objectives for Epizyme's stock. Their predictions range from $20.00 to $28.00. On average, they expect Epizyme's share price to reach $24.25 in the next year. View Analyst Ratings for Epizyme.

What are analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:

  • 1. According to Zacks Investment Research, "Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Additionally, its attempts to evaluate tazemetostat in combination with anti-PD 1 or PDL-1 agent are also encouraging. We believe, the company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. Epizyme’s share price has also outperformed the Zacks classified Medical/Biomedical Genetics industry year to date. However, with no approved product in its portfolio, Epizyme is highly dependent on its collaboration partners for top-line growth. Loss estimates have narrowed ahead of the Q3 earnings results. The company has a positive record of earnings surprises in recent quarters." (10/16/2017)
  • 2. Cann analysts commented, "Epizyme announced today the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts. Epizyme reported that the shares of common stock issued and sold in the offering at the closing included 1,377,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount." (9/19/2017)
  • 3. Cowen and Company analysts commented, "Abstracts from ICML further support BGB-3111’s efficacy profile as being superior." (6/7/2017)

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board
  • Robert B. Bazemore Jr., President, Chief Executive Officer, Director
  • Susan E. Graf, Chief Business Officer, Principal Financial Officer
  • Matthew Ros, Chief Operating Officer
  • Peter T.C. Ho M.D., Ph.D., Executive Vice President, Chief Medical Officer
  • Kevin T. Conroy, Director
  • Andrew R. Allen M.D. Ph.D., Independent Director
  • Kenneth M. Bate, Independent Director
  • Carl S. Goldfischer M.D., Independent Director
  • Richard F. Pops, Independent Director

How do I buy Epizyme stock?

Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of Epizyme stock can currently be purchased for approximately $17.60.


MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Epizyme (NASDAQ:EPZM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.25 (37.78% upside)
Consensus Price Target History for Epizyme (NASDAQ:EPZM)
Price Target History for Epizyme (NASDAQ:EPZM)
Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$23.00MediumView Rating Details
9/19/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$26.00LowView Rating Details
9/19/2017CannReiterated RatingBuy$26.00HighView Rating Details
9/15/2017Royal Bank Of CanadaReiterated RatingBuy$20.00LowView Rating Details
8/9/2017Leerink SwannReiterated RatingOutperform$31.00 -> $28.00MediumView Rating Details
8/7/2017HC WainwrightReiterated RatingBuyMediumView Rating Details
6/16/2017Citigroup Inc.Boost Price TargetBuy$20.00 -> $22.00LowView Rating Details
6/7/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
5/18/2017WedbushReiterated RatingOutperform$24.00HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> OutperformLowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00N/AView Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$21.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Epizyme (NASDAQ:EPZM)
Earnings by Quarter for Epizyme (NASDAQ:EPZM)
Earnings History by Quarter for Epizyme (NASDAQ EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.65)N/AView Earnings Details
8/4/2017Q2 2017($0.56)($0.48)$3.95 million$10.00 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.63)($0.56)$0.49 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.65)($0.60)$0.61 million$0.48 millionViewListenView Earnings Details
11/3/2016Q3($0.60)($0.42)$0.57 million$6.58 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)$0.61 million$0.47 millionViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)$0.58 million$0.47 millionViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)$0.66 million$0.56 millionViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$8.75 million$0.36 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.23 million$0.74 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$6.48 million$0.91 millionViewN/AView Earnings Details
3/12/2015Q414($0.54)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.54)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.46)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.48)($0.22)$7.67 million$13.39 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epizyme (NASDAQ:EPZM)
2017 EPS Consensus Estimate: ($2.54)
2018 EPS Consensus Estimate: ($2.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.65)($0.63)($0.64)
Q2 20174($0.68)($0.41)($0.60)
Q3 20175($0.74)($0.57)($0.65)
Q4 20175($0.73)($0.55)($0.65)
Q1 20182($0.74)($0.54)($0.64)
Q2 20182($0.78)($0.55)($0.67)
Q3 20182($0.77)($0.54)($0.66)
Q4 20182($0.46)($0.11)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Epizyme (NASDAQ:EPZM)
Insider Ownership Percentage: 25.20%
Institutional Ownership Percentage: 72.22%
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Peter Tai-Ching HoInsiderSell15,000$16.81$252,150.00View SEC Filing  
9/18/2017David M MottDirectorBuy200,000$15.25$3,050,000.00View SEC Filing  
8/24/2017Peter Tai-Ching HoInsiderSell15,000$15.68$235,200.00View SEC Filing  
7/24/2017Peter Tai-Ching HoInsiderSell15,000$13.44$201,600.00View SEC Filing  
6/30/2017Andrew E SingerCFOSell3,024$15.50$46,872.00View SEC Filing  
6/26/2017Peter Tai-Ching HoInsiderSell15,000$14.87$223,050.00View SEC Filing  
6/6/2017Robert A CopelandInsiderSell2,500$13.45$33,625.00View SEC Filing  
5/25/2017Peter Tai-Ching HoInsiderSell15,000$16.11$241,650.00View SEC Filing  
5/2/2017Robert A CopelandInsiderSell5,000$17.44$87,200.00View SEC Filing  
4/4/2017Robert A CopelandInsiderSell5,000$16.36$81,800.00View SEC Filing  
3/31/2017Andrew E SingerCFOSell2,013$17.09$34,402.17View SEC Filing  
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.52View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.39View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.20View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.36View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.15View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.65View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.00View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Epizyme (NASDAQ:EPZM)
Latest Headlines for Epizyme (NASDAQ:EPZM)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Epizyme, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 3:31 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 5:06 AM
bizjournals.com logoToday's Research Report Coverage on Biotech Stocks -- Epizyme, FibroGen, Global Blood Therapeutics, and Intercept Pharma
www.bizjournals.com - October 11 at 7:55 PM
americanbankingnews.com logo-$0.65 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter
www.americanbankingnews.com - October 10 at 6:28 PM
finance.yahoo.com logoETFs with exposure to Epizyme, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 6:44 PM
finance.yahoo.com logoEpizyme, Inc. :EPZM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 5:31 PM
americanbankingnews.com logoInsider Selling: Epizyme, Inc. (EPZM) Insider Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 26 at 7:44 PM
americanbankingnews.com logo Brokerages Expect Epizyme, Inc. (EPZM) Will Announce Quarterly Sales of $3.67 Million
www.americanbankingnews.com - September 24 at 10:04 AM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - September 23 at 9:38 PM
americanbankingnews.com logoEpizyme, Inc. Expected to Earn Q3 2017 Earnings of ($0.57) Per Share (EPZM)
www.americanbankingnews.com - September 22 at 6:38 AM
americanbankingnews.com logo-$0.66 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter
www.americanbankingnews.com - September 22 at 2:16 AM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Forecasted to Post FY2017 Earnings of ($2.54) Per Share
www.americanbankingnews.com - September 21 at 9:00 AM
finance.yahoo.com logoEpizyme (EPZM) Looks Good: Stock Adds 7.8% in Session
finance.yahoo.com - September 20 at 7:14 PM
americanbankingnews.com logoFY2020 Earnings Estimate for Epizyme, Inc. (EPZM) Issued By Oppenheimer Holdings
www.americanbankingnews.com - September 20 at 1:56 PM
globenewswire.com logoEpizyme Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 20 at 4:21 AM
finance.yahoo.com logoEpizyme Announces Closing of Public Offering of Common Stock
finance.yahoo.com - September 19 at 6:18 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Reiterates "Buy" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - September 19 at 3:52 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - September 19 at 8:24 AM
americanbankingnews.com logoInsider Buying: Epizyme, Inc. (EPZM) Director Buys 200,000 Shares of Stock
www.americanbankingnews.com - September 18 at 7:24 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 17 at 5:02 AM
finance.yahoo.com logoIs It Too Late To Buy Epizyme Inc (EPZM)? - Yahoo Finance
finance.yahoo.com - September 16 at 4:57 AM
americanbankingnews.com logoRoyal Bank Of Canada Reaffirms "Buy" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - September 15 at 9:14 PM
seekingalpha.com logoEpizyme Striding Into Epigenetic Breakthroughs
seekingalpha.com - September 15 at 6:52 PM
finance.yahoo.com logoWhy Blue Apron Holdings, Tailored Brands, and Epizyme Jumped Today
finance.yahoo.com - September 15 at 6:52 PM
globenewswire.com logoEpizyme Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 14 at 11:58 PM
streetinsider.com logoEpizyme (EPZM) Prices 9.18M Share Offering at $15.25/Sh
www.streetinsider.com - September 14 at 6:56 PM
finance.yahoo.com logoEpizyme Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 14 at 6:56 PM
finance.yahoo.com logoIs It Too Late To Buy Epizyme Inc (EPZM)?
finance.yahoo.com - September 14 at 6:56 PM
streetinsider.com logoAfter-Hours Stock Movers 09/13: (THC) (UNFI) (PCYG) Higher; (ARRY) (VNDA) (EPZM) Lower (more...)
www.streetinsider.com - September 14 at 12:44 AM
nasdaq.com logoTTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red
www.nasdaq.com - September 14 at 12:44 AM
finance.yahoo.com logoEpizyme Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 13 at 7:43 PM
globenewswire.com logoEpizyme to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - August 31 at 12:42 AM
finance.yahoo.com logoEpizyme to Participate in Upcoming Investor Conferences
finance.yahoo.com - August 30 at 7:39 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 23 at 5:06 AM
globenewswire.com logoEpizyme Announces Leadership Transition for Finance Organization - GlobeNewswire (press release)
globenewswire.com - August 16 at 5:09 AM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Expected to Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - August 16 at 12:22 AM
americanbankingnews.com logoLeerink Swann Reiterates Outperform Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - August 9 at 10:58 PM
nasdaq.com logoEpizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2 - Nasdaq
www.nasdaq.com - August 8 at 6:02 AM
finance.yahoo.com logoEpizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : August 7, 2017
finance.yahoo.com - August 7 at 6:36 PM
americanbankingnews.com logoRoyal Bank Of Canada Analysts Give Epizyme Inc (EPZM) a $20.00 Price Target
www.americanbankingnews.com - August 6 at 1:20 PM
finance.yahoo.com logoEdited Transcript of EPZM earnings conference call or presentation 4-Aug-17 12:00pm GMT
finance.yahoo.com - August 5 at 4:42 AM
globenewswire.com logoEpizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress - GlobeNewswire (press release)
globenewswire.com - August 4 at 11:39 PM
finance.yahoo.com logoInvestor Network: Epizyme, Inc. to Host Earnings Call
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoEpizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoEpizyme (EPZM) Reports Narrower-than-Expected Q2 Loss
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoBiotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoEpizyme reports 2Q loss
finance.yahoo.com - August 4 at 6:35 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - August 4 at 5:02 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Scheduled to Post Quarterly Earnings on Friday
www.americanbankingnews.com - August 3 at 8:08 PM
finance.yahoo.com logoFeatured Company News - US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
finance.yahoo.com - August 3 at 3:50 PM

Social

Chart

Epizyme (EPZM) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.